International journal of biological macromolecules · 2025
Surface engineering of biomedical catheters using N-acetyl cysteine functionalized carboxymethyl chitosan nanosystems to combat biofouling and device-associated infections.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yaseen Kinza, Ejaz Sadaf, Imran Muhammad
Аннотация
Functionalized anti-biofouling nanosystems were developed to engineer the surface of silicone catheters for mitigating the incidence of device-associated infections (DAIs). These infections are typically a consequence of microbial biofilms and antimicrobial resistance (AMR) which lead to increased hospitalization costs and mortality rates. Covalent coupling of N-acetyl cysteine (NAC) with O-carboxymethyl chitosan (O-CMC) was optimized to develop NAC-functionalized CMC nanosystems (NAC-CMC-NS). The coupling was confirmed by nuclear magnetic resonance (NMR) spectroscopy, Fourier transform infrared (FTIR) spectroscopy and 4, 6-trinitrobenzene sulfonic acid (TNBS) assay indicating 80 ± 2 % functionalization efficacy. Subsequently, meropenem-loaded NAC-CMC NS exhibited an average particle size of 273 ± 4.2 nm with 0.4 ± 0.03 polydispersity index (PDI), a zeta potential of -9.15 ± 0.5 mV and encapsulation efficiency (EE) of 67 ± 3.2 %. These functionalized NS employing the dual strategy of contact-killing and meropenem-release, exhibited exceptional antimicrobial activity leading to the 76 ± 1.5 % and 60 ± 1 % inhibition of E. coli and P. aeruginosa biofilms, respectively. After the successful grafting of functionalized NS onto silicone catheters, the resulting substrate remarkably reduced the bacterial colonization, offering a promising solution for reducing DAIs like ventilator-associated pneumonia (VAP) and catheter-associated urinary tract infections (CAUTI). Moreover, the excellent hemocompatibility and low cytotoxicity of these nanovesicles highlight their potential applications for clinical use.